Searched for
DR. JOGIN DESAI
Industry sees Budget 2026–27 as execution-oriented, capital-friendly, and future-readyLeaders across private equity, infrastructure, technology, real estate, telecom, and healthcare welcome the Budget’s focus on execution, ca...- Eyestem to begin human trials for its pioneering Dry AMD treatmentDry AMD, a leading cause of vision loss in the ageing population of people over 50, has long been a challenge due to the limited availabili...
- Affordable gene and cell therapies need of the hour: Dr Kapil Bharti, Scientific Director, National Eye InstituteLimitless potential for future global advancements in gene therapies is originating from India, said Dr David Gamm.
- Eyestem files for IND approval for its product to treat geographic atrophyEyestem Research has announced the submission of IND application to CDSCO to start first in-human trials of Eyecyte-RPE™for subjects.
- Eyestem announces US operations with appointment of Ravi Achar and engagement of Stradling advisorsEyestem has appointed Ravi Achar as Head- North America Strategy and also engaged Stradling Yocca Carlson & Rauth as its US law firm.
- Cell therapy startup Eyestem raises ₹51 crore from BE, Alkem & NatcoExisting investors Endiya Partners and Kotak Private Equity also participated in this round, valuing Eyestem at $46.4 million (INR 371 Cror...
Load More